State of New Jersey Common Pension Fund D Makes New Investment in Amneal Pharmaceuticals, Inc. $AMRX

State of New Jersey Common Pension Fund D acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 53,601 shares of the company’s stock, valued at approximately $675,000.

Several other large investors have also made changes to their positions in AMRX. Oliver Luxxe Assets LLC bought a new position in Amneal Pharmaceuticals during the 4th quarter valued at about $1,972,000. AustralianSuper Pty Ltd bought a new stake in Amneal Pharmaceuticals during the third quarter worth about $3,238,000. SG Americas Securities LLC increased its holdings in shares of Amneal Pharmaceuticals by 2,866.0% during the fourth quarter. SG Americas Securities LLC now owns 784,803 shares of the company’s stock worth $9,889,000 after buying an additional 758,343 shares in the last quarter. Citigroup Inc. increased its holdings in shares of Amneal Pharmaceuticals by 55.7% during the third quarter. Citigroup Inc. now owns 282,862 shares of the company’s stock worth $2,831,000 after buying an additional 101,166 shares in the last quarter. Finally, Envestnet Asset Management Inc. bought a new position in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $1,608,000. Institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

AMRX has been the topic of a number of research analyst reports. Truist Financial increased their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. UBS Group assumed coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $19.00 target price on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $15.00.

Amneal Pharmaceuticals Stock Down 3.2%

Amneal Pharmaceuticals stock opened at $12.78 on Tuesday. The business’s 50-day simple moving average is $12.76 and its 200 day simple moving average is $12.77. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of 33.63 and a beta of 1.32. Amneal Pharmaceuticals, Inc. has a 12-month low of $7.02 and a 12-month high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 272.31% and a net margin of 4.01%.The firm had revenue of $722.52 million during the quarter. As a group, sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.